10-Q: BioMarin Reports Q3 Loss Amid Strategic R&D Investment

BioMarin Pharmaceutical Inc. reported a net loss of $30.7 million for the third quarter of 2025, primarily driven by a $221 million acquired in-process R&D expense from the Inozyme Pharma acquisition, despite strong revenue growth from key products.

Summary

• Total revenues for the three months ended September 30, 2025, increased by 4.1% to $776.1 million, up from $745.7 million in the same period last year.
• Net product revenues for the quarter grew to $760.8 million from $733.9 million year-over-year, an increase of $26.9 million.
• The company reported a net loss of $30.7 million for Q3 2025, compared to a net income of $106.1 million in Q3 2024, primarily due to a $221 million acquired in-process research and development (IPR&D) expense from the Inozyme Pharma acquisition.
• Diluted earnings per share (EPS) for Q3 2025 was a loss of $0.16, down from an EPS of $0.55 in Q3 2024.
• For the nine months ended September 30, 2025, total revenues increased by 11.4% to $2,346.7 million, up from $2,106.6 million in the prior year.
• Net income for the nine-month period was $395.5 million, an increase from $301.9 million in the same period last year, with diluted EPS of $2.04 compared to $1.56.
• Gross margin improved to 81.9% for Q3 2025 from 74.7% in Q3 2024, and to 81.2% for the nine-month period from 78.9% in the prior year.
• Research and development (R&D) expenses significantly increased to $409.5 million in Q3 2025 from $184.9 million in Q3 2024, largely due to the Inozyme acquisition.
• Selling, general and administrative (SG&A) expenses increased to $268.4 million in Q3 2025 from $253.5 million in Q3 2024, but decreased for the nine-month period to $706.8 million from $742.4 million.
• Key product revenue drivers for the nine months included VOXZOGO (+$126.9 million), PALYNZIQ (+$53.4 million), and VIMIZIM (+$37.8 million).
• The company announced in October 2025 its plan to pursue options to divest ROCTAVIAN, including exploring out-licensing opportunities.
• Cash and cash equivalents increased to $1,250.1 million as of September 30, 2025, from $942.8 million at December 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company reported a net loss for the quarter, this was primarily due to a significant, one-time strategic R&D investment (Inozyme acquisition). Underlying revenue growth from key products like VOXZOGO and PALYNZIQ remains strong, and year-to-date net income is up. The planned divestment of ROCTAVIAN, while a negative for that specific asset, reflects a strategic portfolio optimization. The company's cash position and operating cash flow are healthy, supporting future investments, though the upcoming convertible debt maturity presents a financing consideration.

Positives

• Total revenues for the nine months ended September 30, 2025, increased by 11.4% to $2,346.7 million, demonstrating strong underlying business growth.
• Net income for the nine-month period increased by $93.6 million to $395.5 million, reflecting improved year-to-date profitability.
• Gross margin significantly improved to 81.9% in Q3 2025 and 81.2% for the nine-month period, driven by favorable product mix and lower per-unit manufacturing costs.
• VOXZOGO sales increased by $28.5 million in Q3 2025 and $126.9 million for the nine-month period, primarily due to new patient initiations across all regions.
• PALYNZIQ sales increased by $18.2 million in Q3 2025 and $53.4 million for the nine-month period, also driven by new patient initiations, primarily in the U.S.
• Positive new data for VOXZOGO demonstrated improved spinal morphology in young children with achondroplasia, supporting its health benefits beyond growth.
• New Phase 3 PEGASUS study data for PALYNZIQ in adolescents showed statistically significant blood phenylalanine lowering.
• BMN 333 (long-acting C-type natriuretic peptide) Phase 1 data in healthy volunteers demonstrated promising pharmacokinetic levels, with no safety signals.
• The acquisition of Inozyme Pharma, Inc. strengthens the enzyme therapies portfolio by adding BMN 401 (formerly INZ-701), a late-stage enzyme replacement therapy for ENPP1 deficiency.
• Net cash provided by operating activities for the nine months increased significantly to $728.4 million from $387.2 million, indicating strong operational cash generation.
• Cash and cash equivalents increased by $307.3 million to $1,250.1 million, enhancing liquidity.

Negatives

• A net loss of $30.7 million was reported for the three months ended September 30, 2025, a significant decline from a net income of $106.1 million in the prior year quarter.
• Diluted EPS for Q3 2025 was a loss of $0.16, compared to an EPS of $0.55 in Q3 2024.
• Research and development expenses increased substantially by $224.6 million in Q3 2025, primarily due to a $221 million acquired in-process R&D charge from the Inozyme acquisition.
• The company announced plans to divest ROCTAVIAN, indicating underperformance or a strategic shift away from this gene therapy product.
• KUVAN revenues decreased by $4.2 million in Q3 2025 and $16.4 million for the nine-month period, attributed to increasing generic competition and loss of market exclusivity.
• NAGLAZYME sales decreased by $9.9 million in Q3 2025 due to timing of large government orders, primarily in Latin America.
• ALDURAZYME sales decreased by $17.3 million in Q3 2025 due to timing of order fulfillment to Sanofi.
• ROCTAVIAN sales decreased by $4.0 million in Q3 2025, reflecting reduced commercial efforts and the planned divestment.

Risks

• The ability to manage growth and execute the new corporate strategy, including expanding VOXZOGO indications and integrating acquisitions like Inozyme, may be impaired.
• Acquisitions, such as Inozyme Pharma, Inc., could divert management's attention, fail to achieve anticipated benefits, or expose the company to integration difficulties and other risks.
• Failure to achieve projected development goals in announced timeframes could delay or prevent commercialization of product candidates and adversely affect management credibility and stock price.
• Intense competition in product sales, including from more effective or less expensive products and generic versions (e.g., KUVAN), could adversely affect revenues and profitability.
• Failure to obtain and maintain adequate coverage and reimbursement for products by third-party payers could adversely affect sales or eliminate commercially viable markets.
• Changes in methods of disease treatment (e.g., gene therapy impacting enzyme replacement therapy) or failure of products to gain acceptance by patients or the medical community could negatively impact demand and revenues.
• Failure to obtain regulatory approval for product candidates or delays in approval could prevent revenue generation and increase capital needs.
• Ongoing extensive regulatory requirements for approved products, including cGMP, post-marketing studies, and REMS programs (e.g., PALYNZIQ), could lead to penalties, revenue loss, or increased costs if not complied with.
• Preclinical studies and clinical trials are costly, lengthy, and highly uncertain, with preliminary data not necessarily predictive of final results, posing risks to product approval.
• Government price controls, healthcare reform (e.g., Inflation Reduction Act, PPACA), and other pricing regulations could restrict charges for products and adversely affect revenues and results of operations.
• Failure to obtain the capital necessary to fund operations, including repayment of convertible debt due in 2027, future milestone payments, and R&D, could adversely affect financial results and force program delays or terminations.
• Non-compliance with manufacturing regulations (cGMP) could lead to delays, fines, recalls, production suspensions, or enforcement actions.
• Inability to successfully develop and maintain manufacturing processes to produce sufficient quantities at acceptable costs could hinder clinical trials, commercial demand, or force program termination.
• Supply interruptions from single-source suppliers for critical raw materials or limited manufacturing facilities could disrupt inventory, product availability, and delay regulatory approvals.
• International operations, which generate a significant portion of sales, are subject to increased complexity, diverse regulatory requirements, geopolitical instability, diminished intellectual property protection, trade issues, and currency risks.
• Reliance on special access programs for international sales exposes the company to risks from changes in program requirements, funding levels, and unofficial measures by governments to limit purchases.
• Exposure to movements in foreign currency exchange rates, particularly for unhedged currencies like the Argentine Peso, could adversely affect operating results and net income.
• Inability to protect intellectual property (patents, trade secrets) could lead to ineffective competition or loss of market share, especially given public domain information for some product candidates.
• Competitors and other third parties may have intellectual property that limits the ability to market and commercialize products, potentially leading to lawsuits, substantial damages, or licensing requirements.
• Stock price volatility due to various factors, including product sales, regulatory progress, competition, economic conditions, and activist investor actions, could lead to a decline in investment value.
• New tax laws or regulations (e.g., OBBB Act, BEPS 2.0) or adverse interpretations could materially affect the business and financial condition.
• Violations of healthcare laws (anti-kickback, false claims, data privacy, Physician Payments Sunshine Act) could result in penalties, regulatory scrutiny, or suspension from government healthcare programs.
• Reliance on information technology systems and vulnerability to cybersecurity incidents could harm business operations, reputation, and financial condition.
• Natural disasters, terrorist activity, or other unforeseen events causing significant damage to facilities or those of third-party manufacturers/suppliers could disrupt operations and reduce revenues.
• Macroeconomic conditions, including inflation, interest rates, geopolitical instability, and global public health threats, could adversely affect business, financial results, and access to capital.

Future Outlook

The company plans to continue growing its commercial business and advancing its product candidate pipeline, including pursuing options to divest ROCTAVIAN while maintaining its commercial availability in key markets. Strategic portfolio assessments will continue to guide R&D program decisions, with a focus on expanding VOXZOGO's indications beyond achondroplasia to include hypochondroplasia, idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency. The company is evaluating the full impact of the One Big Beautiful Bill (OBBB) Act on its tax disclosures and will continue the phased deployment of its new ERP system through 2026. Management anticipates needing additional financing to fund the repayment of its convertible debt due in May 2027 and future operations, including R&D, potential licenses, and acquisitions.

Management Comments

• We believe that the combination of our internal research programs, partnerships and acquisitions of external assets will allow us to continue to develop and commercialize innovative therapies for patients with serious and life-threatening rare diseases and medical conditions.
• We periodically conduct strategic portfolio assessment of research and development programs to determine which we believe have the strongest combination of scientific merit, opportunity for commercial success and potential value creation for stockholders.
• In October 2025, we announced our plan to pursue options to divest ROCTAVIAN, including exploring out-licensing opportunities. We plan to continue to make ROCTAVIAN commercially available in the U.S., Italy and Germany until next steps are finalized.
• The acquisition of Inozyme Pharma, Inc. is intended to strengthen our enzyme therapies portfolio by adding a late-stage enzyme replacement therapy, BMN 401, for the treatment of ENPP1 deficiency.
• We believe cash generated from sales of our commercial products, in addition to our cash, cash equivalents and short-term investments will be sufficient to satisfy our liquidity requirements for at least the next 12 months.

Industry Context

BioMarin operates in the highly specialized and competitive rare disease biotechnology sector, characterized by high R&D costs and the need for significant market share at high per-patient prices due to small patient populations. The industry faces increasing scrutiny over drug pricing, with government healthcare reforms like the U.S. Inflation Reduction Act and EU HTA regulations exerting downward pressure on reimbursement and potentially impacting market exclusivity. The shift towards gene therapies, while offering new treatment paradigms, also poses a potential competitive threat to established enzyme replacement therapies. The sector is also navigating evolving global data privacy laws, cybersecurity threats, and macroeconomic volatilities, including inflation and foreign currency fluctuations, which can impact supply chains and operational costs. Strategic acquisitions, like that of Inozyme Pharma, are a common industry trend to expand pipelines and leverage specialized expertise, while divestments of underperforming assets, such as ROCTAVIAN, reflect ongoing portfolio optimization in a dynamic market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking against industry standards. However, the company's focus on rare diseases and high per-patient pricing aligns with the general business model for orphan drugs, where smaller patient populations necessitate higher prices to recoup significant R&D and manufacturing costs.
• The reported gross margin of 81.9% for Q3 2025 and 81.2% for the nine-month period is generally strong for the pharmaceutical industry, particularly for specialty and orphan drugs, indicating efficient cost of sales relative to revenue for its core products.
• The significant increase in R&D expenses, particularly the $221 million IPR&D charge from the Inozyme acquisition, is typical for a biotechnology company actively expanding its pipeline through M&A, reflecting substantial investment in future growth rather than operational inefficiency.
• The planned divestment of ROCTAVIAN, a gene therapy, suggests that its commercial performance did not meet internal expectations or market potential, a common challenge in the high-risk, high-reward gene therapy space where commercial uptake can be slower than anticipated.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a subpoena from the U.S. Department of Justice (DOJ) requesting documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME. The company has produced the requested documents and is cooperating fully, but the outcome of the investigation and its potential impact on the business and financial statements are uncertain.

Related Party Transactions

• ALDURAZYME is a registered trademark of BioMarin/Genzyme LLC, and is distributed, marketed, and sold exclusively by Sanofi worldwide. The accounts receivable balance for Sanofi included $135.7 million as of September 30, 2025, and $96.8 million as of December 31, 2024, of unbilled accounts receivable.

Stakeholder Impact

• Shareholders: The Q3 net loss and ROCTAVIAN divestment could lead to short-term stock price volatility, while strategic acquisitions and pipeline advancements offer long-term growth potential. Dilution risk exists from potential future equity financing.
• Employees: The workforce reduction of approximately 395 employees in Q2 and Q3 2024 could impact morale and retention, while new management appointments and strategic shifts may create new opportunities and challenges.
• Customers: Continued availability of ROCTAVIAN in key markets despite divestment plans, and expansion of VOXZOGO indications, aim to serve broader patient populations. However, generic competition for KUVAN and potential pricing pressures from healthcare reforms could affect product access and affordability.
• Suppliers: Reliance on single-source suppliers for critical raw materials and limited manufacturing facilities creates supply chain risks, potentially impacting product availability.
• Creditors: The $600 million convertible debt due in May 2027 highlights a future liquidity requirement, which may necessitate refinancing or additional capital, impacting credit risk.

Next Steps

• Pursue options to divest ROCTAVIAN, including exploring out-licensing opportunities, while continuing its commercial availability in the U.S., Italy, and Germany.
• Continue to provide support and monitoring for people treated with ROCTAVIAN.
• Advance VOXZOGO for the treatment of conditions beyond achondroplasia, including hypochondroplasia, idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency.
• Continue the phased deployment of the new enterprise resource planning (ERP) system through 2026, with post-implementation activities following thereafter.
• Evaluate the full impact of the One Big Beautiful Bill (OBBB) Act on related disclosures as additional guidance becomes available.
• Monitor and manage responses to macroeconomic conditions and assess impacts on operating results and financial condition.

Key Dates

Recommendation

The company is in a period of strategic repositioning, marked by a significant acquisition (Inozyme Pharma) that led to a one-time R&D charge and a quarterly net loss. While this short-term loss is a concern, the underlying business shows strong revenue growth from key products like VOXZOGO and PALYNZIQ, and year-to-date profitability remains positive. The decision to divest ROCTAVIAN, an underperforming asset, is a prudent move for portfolio optimization. However, the company faces ongoing risks from generic competition (KUVAN), regulatory pressures (IRA, EU HTA), and the need to address the 2027 convertible debt maturity. Given the mixed signals of strategic investment and underlying growth alongside specific product challenges and market risks, a 'hold' recommendation is appropriate, allowing investors to observe the execution of the new corporate strategy and the performance of the strengthened pipeline.

Keywords

BioMarin, BMRN, Rare Disease, Biotechnology, Pharmaceutical, VOXZOGO, PALYNZIQ, VIMIZIM, NAGLAZYME, ALDURAZYME, BRINEURA, KUVAN, ROCTAVIAN, Inozyme Pharma, BMN 401, ENPP1 Deficiency, Achondroplasia, Phenylketonuria, MPS IVA, MPS VI, MPS I, CLN2, Hemophilia A, Gene Therapy, Enzyme Replacement Therapy, Q3 2025, Financial Results, SEC Filing, R&D Expense, Acquisition, Divestment